Pure Global AI
NCT06094530Recruiting

18F-FAPI-RGD PET/CT in Various Tumor Types

Clinical Evaluation of 18F-FAPI-RGD PET/CT for Imaging of Fibroblast Activation Protein and Integrin avb3 in Various Tumor Types
Sichuan Provincial People's HospitalClinicalTrials.gov
Verified
Study focus
Disease/Condition
Neoplasms
Study type
Observational
Sponsor & location
Primary sponsor
Sichuan Provincial People's Hospital
Location
Chengdu, China
Timeline & enrollment
Phase
N/A
Start date
Apr 10, 2023
End date
Oct 01, 2024
Enrollment
100 participants
Primary outcome

Comparison of 18F-FAPI-RGD and 18F-FDG Uptake in Patients with different Tumors

Summary

The clinical feasibility of 18F-FAPI-RGD PET/CT will be evaluated in 100 patients with
 various types of tumor, and the results will be compared with those of 18F-FDG.

ICD-10 classifications
NeoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasmsMalignant neoplasms
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06094530
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06094530 through Pure Global AI's free database. This phase not specified trial is sponsored by Sichuan Provincial People's Hospital and is currently Recruiting. The study focuses on Neoplasms. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.